May 13, 2020 / 5:15 PM / 17 days ago

BRIEF-Roivant Provides Updates For Pivotal Breathe Clinical Trial Evaluating Gimsilumab In COVID-19 Patients

May 13 (Reuters) - ROIVANT SCIENCES :

* ROIVANT PROVIDES UPDATES FOR PIVOTAL BREATHE CLINICAL TRIAL EVALUATING GIMSILUMAB IN COVID-19 PATIENTS FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME

* ROIVANT SCIENCES - INDEPENDENT DATA MONITORING COMMITTEE UNANIMOUSLY RECOMMENDS BREATHE TRIAL CONTINUATION AFTER PRE-SPECIFIED SAFETY ASSESSMENT

* ROIVANT SCIENCES - BREATHE TRIAL PARTICIPANTS WILL BE PERMITTED TO USE INVESTIGATIONAL ANTIVIRALS INCLUDING REMDESIVIR

* ROIVANT SCIENCES - GIMSILUMAB HAS DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE BASED ON DATA COLLECTED TO DATE Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below